Neurogene Inc.NGNEEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Neurogene Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for patients with rare, genetically driven neurological disorders that have significant unmet medical needs, with its primary operating markets spanning North America and Europe.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Samsara BioCapital, L.P. | 11.60% | 1.7M | ▲ +1.61pp | 2024-11-27 |
| BlackRock, Inc. | 10.70% | 1.4M | — | 2024-07-08 |
| EcoR1 Capital, LLC | 9.99% | 1.3M | — | 2024-02-14 |
| Rachel McMinn, Ph.D. | 9.90% | 1.3M | — | 2023-12-21 |
| RTW Investments, LP | 8.70% | 1.1M | — | 2024-11-14 |
| Redmile Group, LLC | 8.10% | 1.1M | ▼ -1.80pp | 2024-02-14 |
| Great Point Partners, LLC | 7.73% | 1.0M | flat | 2024-11-14 |
| Casdin Capital, LLC | 6.90% | 1.0M | — | 2024-11-08 |
| FMR LLC | 5.63% | 731.8K | — | 2024-11-12 |
| S.S. OR | 5.50% | 709.5K | ▼ -1.10pp | 2024-11-14 |
| Commodore | 5.40% | 800.0K | — | 2024-12-11 |
| Baker Bros. Advisors LP | 4.99% | 649.6K | — | 2023-12-20 |
| Cormorant Global Healthcare Master Fund, LP | 1.21% | 155.8K | — | 2024-02-14 |
| Cormorant Asset Management, LP | 0.83% | 107.3K | — | 2024-11-14 |
| Lynx1 Capital Management LP | 0.10% | 64.0K | — | 2024-02-14 |
Insider Transactions
Net 90d: −$493.6K · buys $0 / sells $493.6KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-26 | McMinn Rachel | Chief Executive Officer | Sell (open market) | 3.4K | $22.07 | $74.0K |
| 2026-03-26 | Cvijic Christine Mikail | President and CFO | Sell (open market) | 2.6K | $21.62 | $55.3K |
| 2026-03-26 | Julie Jordan | Chief Medical Officer | Sell (open market) | 828 | $21.89 | $18.1K |
| 2026-03-13 | Stuart Cobb | Chief Scientific Officer | Sell (open market) | 4.0K | $20.41 | $81.5K |
| 2026-03-13 | Stuart Cobb | Chief Scientific Officer | Sell (open market) | 2.7K | $21.34 | $56.7K |
| 2026-03-13 | Stuart Cobb | Chief Scientific Officer | Sell (open market) | 148 | $22.08 | $3.3K |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Sell (open market) | 2.4K | $20.42 | $48.7K |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Sell (open market) | 1.4K | $21.25 | $29.6K |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Sell (open market) | 263 | $22.02 | $5.8K |
| 2026-02-27 | Cvijic Christine Mikail | President and CFO | Sell (open market) | 4.8K | $25.11 | $120.5K |
1–10 of 10